EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual antiplatelet therapy (DAPT) after complex percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS).

The study aimed to determine whether anatomical PCI complexity modifies the effects of treatment — aspirin-free monotherapy versus DAPT — on ischemic and bleeding outcomes.

A total of 3,410 ACS patients successfully treated with PCI across 50 centers in Brazil were analyzed. Complex PCI was defined by the presence of at least one of the following criteria: treatment of ≥3 vessels, ≥3 lesions treated, or ≥3 stents implanted; total stent length >60 mm; bifurcation treated with two stents; left main coronary intervention; bypass graft treatment; or chronic total occlusion (CTO).

The analysis showed that PCI complexity did not modify the treatment effect between potent P2Y12 inhibitor monotherapy and DAPT. No significant differences were observed in ischemic events, defined as death, myocardial infarction, stroke, or urgent revascularization.

Read also: EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results.

In the complex PCI group, the incidence of ischemic events was 7.3% with monotherapy versus 5.3% with DAPT.

On the other hand, monotherapy substantially reduced clinically relevant bleeding compared with DAPT, regardless of whether PCI was complex or non-complex (p for interaction = 0.73). In complex cases, bleeding occurred in 2.4% of patients treated with monotherapy versus 5.5% of those treated with DAPT.

Although monotherapy consistently reduced bleeding, no clear net clinical benefit was demonstrated due to the lack of non-inferiority regarding ischemic endpoints.

Conclusions: Early Aspirin Withdrawal May Reduce Bleeding Even in Complex PCI

Anatomical PCI complexity does not appear to be a significant modifier of the effects of P2Y12 inhibitor monotherapy compared with DAPT in patients with acute coronary syndrome. This study provides the first evidence regarding very early aspirin withdrawal in this patient population stratified according to anatomical complexity.

Original Title: P2Y12 Inhibitor Monotherapy vs DAPT After Complex PCI in ACS

Reference: Guy Prado et al EuroPCR 2026.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Andrés Rodríguez
Dr. Andrés Rodríguez
Member of the Editorial Board of solaci.org

More articles by this author

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...